The fate of cellular mRNAs was analyzed in several cell lines of lymphoid origin, after induction of apoptosis by different mechanisms. Cytoplasmic mRNAs are specifically degraded as part of the early apoptotic response. This degradation is not species restricted and is independent of the cell line, the apoptotic stimulus, the intrinsic half-life of the mRNAs, and the transcriptional status of the gene (constitutive or inducible). mRNA degradation precedes DNA fragmentation and correlates with the appearance of phosphatidylserine in the outer cell membrane. In addition, apoptosis-induced mRNA degradation is an active process that can be dissected from other apoptotic hallmarks (degradation of annexin V, DNA, and poly(ADP-ribose) polymerase [PARP]), which suggests that apoptosis-induced mRNA degradation is controlled by a distinct signaling pathway. Furthermore, mRNA degradation also occurs in vivo, specifically during thymocyte apoptosis. Taken together, these data support the notion that degradation of mRNA is a general early apoptotic event that may become a new apoptotic hallmark.
In the immune system, apoptosis plays a key role both in the control of lymphocyte maturation and in the maintenance of homeostasis of mature cell populations. During maturation, thymocytes undergo positive and negative selection, so that only about 5% successfully complete maturation and leave the thymus, and the large majority of immature cells die by apoptosis (20, 21) . In addition, during an immune response, mature T cells of the appropriate antigenic specificity undergo clonal expansion and acquire effector functions, leading to antigen elimination. After antigen removal, the majority of expanded T cells must be eliminated to maintain homeostasis, while a small fraction of the T cell population remains as long-lasting memory cells. Apoptosis induced either by death receptor triggering or by growth factor deprivation has been implicated in the elimination of the majority of these clonally expanded T cells (22, 23) . T-cell receptor (TCR) cross-linking leads to activation of resting T cells, whereas it induces apoptosis (activation-induced cell death [AICD]) in activated T cells (24) . AICD has also been implicated in apoptosis during thymocyte development (25) and in the depletion of autoreactive T cells (24, 26) . Furthermore, growth factor deprivation-induced apoptosis is independent of Fas-mediated signaling pathways, because patients with autoimmune lymphoproliferative syndrome have AICD defects (27, 28) despite normal growth factor deprivation-induced apoptosis (29) .
The fate of cytoplasmic mRNAs was analyzed after triggering of apoptosis by direct crosslinking of the death receptor CD95, AICD, or growth factor deprivation. These experiments demonstrated that mRNA degradation is a general early apoptotic event taking place in all the analyzed cell lines, and also during in vivo physiological situations. Apoptosis-induced mRNA degradation is independent of the stimulus used, precedes DNA fragmentation, and is an active process that can be dissected from DNA fragmentation, PARP processing, and annexin V binding by the use of caspase inhibitors. These data suggest that a distinct signaling pathway, induced by death receptor triggering, is responsible for mRNA degradation during apoptosis.
MATERIALS AND METHODS

Cell lines, culture conditions, and reagents
A20 (ATCC No. TIB208) is a mature murine (BALB/c) B cell line (30) (provided by Dr. Brás). CTLL-2 (ATCC No. TIB214) is a mouse cytotoxic T-cell clone requiring exogenous interleukin 2 (IL-2) for growth (31) (a gift from Dr. Erard). J-HM1-2.2 cells (hereafter referred to as JHM12) is a Jurkat derivative constitutively expressing the human muscarinic type I receptor (HM1R) (32) (provided by Dr. Weiss). JHM12-p35 was derived from JHM12 cells after the cDNA coding for the Autographa californica p35 gene was stably transfected under the control of the EF1α promoter. Transfectants were selected by five rounds of treatment with anti-CD95 monoclonal antibody (mAb) (50 ng/ml, 48 h). Molt-4 (ATCC No. CRL-1582) is a human acute lymphoblastic leukemia cell line, which undergoes apoptosis after treatment with 316 nM okadaic acid (33) . All cells were cultured in IMDM-10 (Iscove's modified Dulbecco's medium containing 10% heat-inactivated FCS, 10 mM 4-(2-hydroxyethyl)-piperazine-1-ethanesulfonic acid [HEPES] pH 7.0, 0.05 mM β-mercaptoethanol, and 2 mM glutamine). CTLL-2 cells were supplemented with saturating concentrations of mouse rIL-2 (34).
AICD was induced in JHM12 cells (10 6 cells/ml) by activation with 500 µM carbachol (Sigma, St. Louis, MO) (35) or plate-coated 10 µg/ml anti-CD3ε mAb (T3b). For direct CD95 triggering of A20 or JHM12, these cells were treated with 50 ng/ml Jo2 mAb (PharMingen, San Diego, CA) or CH-11 mAb (Upstate Biotechnology, Lake Placid, NY), respectively. For mRNA halflife measurements, JHM12 cells were treated with carbachol (500 µM, 1 h) before addition of 5 µM actinomycin D; this concentration of actinomycin D inhibits more than 90% of [ 3 H]UTP incorporation into trichloroacetic acid precipitable counts (not shown). Apoptosis caused by growth factor deprivation was induced in exponentially growing CTLL-2 cells after cells were washed three times in fresh IMDM-10 medium and were then resuspended at 0.5 × 10 6 cells/ml in fresh IMDM-10 devoid of IL-2. The irreversible and cell-permeable caspase inhibitor Z-VAD-fmk (Z-Val-Ala-Dl-Asp fluoromethylketone; No. N1510; Bachem, Bubendorf, Switzerland) was added at a final concentration of 100 µM at the specified times. 
Antigen-induced thymocyte apoptosis
CD8
+ cells are affected). Ninety minutes after injection, animals were killed by cervical dislocation, single thymocyte cell suspensions were obtained and minced through a 150-µm nylon mesh, and aliquots were used for analysis of 1) thymocyte subpopulations after staining with CD4 and CD8 mAb (1 × 
Cytofluorometric analysis
After induction of apoptosis, annexin V binding to phosphatidylserine exposed on the outer surface of the membrane was measured by flow cytometry with fluorescein isothiocyanate (FITC)-labeled annexin V (Immunotech, Marseille, France). For cell cycle analysis, cells were permeabilized, were stained with propidium iodide (DNA-Prep Reagents Kit, Beckman Coulter, Miami, FL), and, after RNA digestion (30 min, 37°C), were analyzed by flow cytometry to determine the fraction of surviving cells (G 0 /G 1 , S, and M phases of the cell cycle) and nonviable cells (sub-G 0 /G 1 phase). Cell suspensions from the thymus were stained with saturating concentrations of anti-CD4-FITC mAb and anti-CD8-phyco mAb (PharMingen) and were evaluated by multiparameter analysis.
Western blot analysis
Cytosolic cell extracts were prepared by incubation (30 min, 4°C) in extraction buffer (50 mM Tris-HCl pH 7.6, 150 mM NaCl, 0.5 mM EDTA, 1% Nonidet-P40, 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml aprotinin, 10 µg/ml leupeptin, and 1 µg/ml pepstatin), followed by high-speed centrifugation of lysates. Cytosolic extracts (30 µg/lane) were resolved by 8% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes (BioRad, Hercules, CA). Western blots were performed with an anti-human PARP mAb, which recognizes mouse and human PARP (Labgen, Oxford, UK; 1:750 dilution), followed by horseradish peroxidase-conjugated anti-mouse IgG (Dako, Glostrup, Denmark), and blots were developed by enhanced chemiluminescence (Amersham Pharmacia Biotech, Uppsala, Sweden).
RNA preparation and analysis
Cytoplasmic RNA was prepared by using the NP40 method (37); thymocyte total RNA was prepared by the guanidinium-thiocyanate-acid phenol method (37) . After electrophoresis through denaturing 1.2% formaldehyde-agarose gels, RNA samples were transferred to nylon membranes (GeneScreen, New England Nuclear, Boston, MA), and rRNA distribution was visualized by methylene blue staining (38) . Northern blots were hybridized sequentially with specific cDNA probes labeled either with [α 32 P]dCTP by using the random priming method or with [α 32 P]CTPlabeled cRNA probes (39). For 28S rRNA analysis, an oligonucleotide complementary to nucleotides 4205-4225 (provided by Dr. E. W. Müllner) was end-labeled with [γ-32 P]ATP using poly-nucleotide kinase. After samples were washed, filters were exposed and quantified by phosphorimaging (Molecular Dynamics, Sunnyvale, CA). The background from each sample was subtracted by using the local median algorithm of the program ImageQuant (v.1.2, Molecular Dynamics).
DNA fragmentation assays
Analysis of DNA fragmentation was carried out as described previously (40) , followed by incubation with 10 µg of RNase A (30 min, 37°C), subsequent electrophoresis in 2% agarose gels, visualization by ethidium bromide staining, and photography after UV light exposure.
RESULTS
CD95-induced apoptosis triggers degradation of cytoplasmic mRNAs
Direct CD95 cross-linking with its specific ligand (Fas-L) or with agonistic mAb induces apoptosis in activated T cells and T-cell lymphomas (41) . In Jurkat cells treated with 50 ng/ml anti-CD95 mAb, onset of apoptosis can be ascertained by 1) appearance of phosphatidylserine in the outer cell membrane, as measured by annexin V binding; 2) processing of the caspase substrate PARP; and 3) degradation of nuclear DNA, quantified by an increase in the fraction of cells in the sub-G 0 /G 1 cell cycle phase. As early as 1 h after apoptotic insult, there was a significant increase in the amount of processed PARP and detectable annexin V binding, both of which increased over time. At 5 h after CD95 triggering, 62% of cells were positive for annexin V and the vast majority of PARP had been processed (Fig. 1A ). These changes were followed by an increase in the fraction of cells in the sub-G 0 /G 1 cell cycle phase (Fig. 1A) . Thus, this model functions as a suitable tool for analysis of the fate of cellular mRNA during apoptosis.
The analysis of the mRNAs coding for the T-cell receptor β chain (TCRβ), major histocompatibility complex (MHC) class I α-chain (HLA-I), and β-actin revealed a substantial decrease in expression levels of all these mRNAs after induction of apoptosis (Fig. 1B) because of mRNA degradation (see below). mRNA degradation kinetics paralleled the appearance of annexin V-positive cells and preceded nuclear DNA fragmentation (Fig. 1C ). In addition, the methylene blue staining pattern of RNA samples indicated degradation of 28S rRNA (Fig. 1B , open arrowheads). Specificity of apoptotis-induced mRNA degradation was demonstrated by processing Jurkat cells alone (−A20) or mixed, before lysis and RNA preparation, with A20 mouse control cells (+A20), followed by Northern hybridization with human-and mousespecific probes. Similar degradation kinetics were observed for human mRNAs when samples of Jurkat cells were processed either alone (−A20) or mixed with nonapoptotic control cells (+A20), whereas mouse-specific IAα mRNA levels remained unchanged in samples containing control cells (+A20) and were undetectable in samples devoid of control cells (−A20). Taken together, these data indicate that CD95 triggering induces specific mRNA degradation, as part of the early apoptotic response, in Jurkat cells.
The Jurkat cell model also allowed analysis of mRNA degradation during AICD, one of the major mechanisms controlling immune system homeostasis (1). The fate of genes expressed in a constitutive (TCRβ, HLA-I, and β-actin) or inducible (early activation marker CD69) fashion, as well as 28S rRNA, was analyzed in JHM12 cells after carbachol treatment, which induces AICD in these cells (35) . In agreement with the findings for CD95-induced apoptosis, all mRNAs analyzed after AICD were rapidly degraded, which correlated with the appearance of annexin V binding (Fig. 2) . The similar degradation kinetics of Jurkat mRNAs in the presence (+A20) or absence (−A20) of control cells, whereas the A20-specific mRNA (IAα) remained intact ( Fig. 2) , again indicated specificity of the apoptosis-induced mRNA degradation. The apparent difference in β-actin degradation kinetics between samples containing Jurkat mRNAs alone or mixed with A20 can be explained by the cross-reactivity of this probe between mouse and human samples (Fig. 2) . The 28S rRNA probe also cross-reacts with mouse and human samples, but degradation of this rRNA could be quantified by appearance of specific degradation products (a 20-fold increase in the 28S rRNA degradation product was concomitant with a 5-to 33-fold degradation of the mRNAs 8 h after apoptosis triggering) ( Fig. 2A) , which showed similar kinetics in the presence or absence of control A20 cells (Fig. 2B, inset ).
These data show that after apoptosis induction in Jurkat cells, by either direct CD95 crosslinking or AICD, cytoplasmic mRNA degradation is an early event, concomitant with the appearance of annexin V-positive cells ( Figs. 1 and 2 ). This degradation affects all mRNAs analyzed, independently of the transcriptional status of the gene, as well as 28S rRNA.
To demonstrate that the apoptosis-induced decline in mRNA hybridization signals was indeed due to an active degradation rather than to an apoptosis-induced transcriptional arrest, mRNAs half-lives in nonapoptotic cells were analyzed and shown to be different from the apoptosisinduced degradation kinetics. Cells were preactivated with carbachol (1 h) before transcription was blocked with actinomycin D, to allow mRNA half-life analysis of activation-inducible (CD69) transcripts and of constitutive mRNAs. This short activation is not sufficient to trigger apoptosis because, during the course of the experiment, there was no significant increase in the fraction of annexin V-positive cells and PARP processing was detected only at longer times (>3 h, even in the absence of transcription inhibitors, not shown). In JHM12 cells, CD69 mRNA had a short half-life (about 20 min), as previously reported (42), whereas the other mRNAs did not decay significantly during the course of the experiment (Fig. 3) . Actinomycin D treatment, although restricted to 4 h because of toxicity at longer treatment times, allowed us to estimate that HLA-I, β-actin, and TCRβ mRNA half-lives were longer than 10 h, in accordance with published data (43, 44) . Thus, mRNAs with different half-lives showed similar apoptosisinduced degradation kinetics, indicating that apoptosis-induced mRNA degradation is an active process.
Apoptosis-induced mRNA degradation was a general event independent of cell type and apoptosis triggering pathway
To exclude the possibility that apoptosis-induced mRNA degradation was restricted to the JHM12 Jurkat T-cell clone, apoptosis was induced in mouse A20 cells (used as control in the above experiments) by direct CD95 cross-linking with mAb. A20 mRNAs (IAα, BAX) were degraded during CD95-induced apoptosis, whereas HLA-I mRNA from mixed control Jurkat cells remained intact (Fig. 4) , which again demonstrated the specificity of the apoptosis-induced mRNA degradation. The kinetics of apoptosis-induced mRNA degradation also correlated with increased annexin V binding. These data demonstrated that apoptosis-induced mRNA degradation was not restricted by cell line and strengthened the idea that it is an early general mechanism affecting different mRNAs, including those encoding proteins implicated in cell death, such as the proapoptotic protein BAX (45, 46) .
In addition to AICD, growth factor deprivation is the other major mechanism that induces T-cell apoptosis and allows maintenance of T-cell homeostasis after clonal expansion. The IL-2-dependent murine cytotoxic T lymphocyte cell line CTLL-2 was used as a model for growth factor deprivation-induced apoptosis. In these cells, IL-2 withdrawal induced an increase in the sub-G 0 /G 1 cell fraction, which indicated DNA degradation (Fig. 5A) . It is noteworthy that in comparison to CD95 cross-linking and AICD, the appearance of annexin V-positive cells was delayed, rather than preceding DNA fragmentation, and had kinetics similar to the kinetics of DNA fragmentation (Fig. 5B) . 28S rRNA degradation and appearance of the characteristic intermediates were detectable within 12 h after growth factor withdrawal (Fig. 5A) . β-Actin mRNA, as an example of cytoplasmic transcript, was also degraded as an early event detectable after 12 h, in fact preceding both the appearance of annexin V binding and DNA fragmentation (Fig. 5B) .
Distinct pathways lead to mRNA degradation and other apoptotic hallmarks after CD95 cross-linking
Because CD95-induced apoptosis is inhibited by the general caspase inhibitor Z-VAD-fmk, its effect on apoptosis-induced mRNA degradation was analyzed. As expected, pretreatment with 100 µM Z-VAD-fmk inhibited the increases in annexin V binding, cells in the sub-G 0 /G 1 phase of the cell cycle, and PARP processing, which were induced by 5 h anti-CD95 mAb, as well as cytoplasmic mRNA degradation, in both A20 and Jurkat cells (Fig. 6 ).
When apoptosis was induced in A20 cells for 6 h with anti-CD95, and the caspase inhibitor Z-VAD-fmk was added at different times, conditions could be defined in which all described apoptotic events, except for mRNA degradation, were abrogated. Indeed, whereas Z-VAD-fmk addition either 1 h before or at the same time as anti-CD95 led to complete inhibition of all apoptotic markers including mRNA degradation, its addition 0.5 h after anti-CD95 mAb revealed degradation of more than 50% of the mRNA, with no detectable PARP processing and only background levels of DNA degradation or annexin V binding (Fig. 7) . When Z-VAD-fmk was added at later times after CD95 triggering, a similar fraction of mRNA was degraded, concomitant with a progressive increase in PARP processing, annexin V-positive cells, and cells in the sub-G 0 /G 1 phase of the cell cycle (Fig. 7) . Similar results were obtained with JHM12 cells (not shown). Thus, these data allowed us to conclude that apoptosis-induced mRNA degradation can occur in the absence of other apoptotic markers. Z-VAD-fmk inhibition kinetics also showed striking differences between mRNA degradation and annexin V binding, DNA degradation, and PARP degradation, the last three being progressively abrogated. This result indicates that anti-CD95 mAb triggers different downstream signaling pathways, one responsible for annexin V binding, DNA fragmentation, and PARP processing, and the other implicated in mRNA degradation.
In addition, mRNA degradation was analyzed in JHM12-p35 cells, in which anti-CD95 mAbinduced apoptosis was completely blocked by constitutive expression of the baculoviral caspase inhibitor p35. Indeed, p35 expression abrogated DNA fragmentation and inhibited appearance of annexin V-positive cells. Most interesting, although the cells kept proliferating at the same rate, a substantial fraction of mRNA was still degraded (Fig. 8) . These data further substantiate the notion of a distinct downstream signaling pathway responsible for mRNA degradation during apoptosis.
Taken together, these data show that apoptosis induces, as an early event, degradation of mRNAs with different intrinsic half-lives by an active process, as demonstrated by transcriptionblocking experiments. The pathways can be dissected from the one leading to the other apoptotic hallmarks. These data also demonstrate that although apoptosis-induced mRNA degradation is not restricted by cell line or stimuli, it is not sufficient to induce cell death.
Apoptosis-induced mRNA degradation occurs in vivo as an early apoptotic event
To determine whether apoptosis-induced mRNA degradation was a general apoptosis marker rather than restricted to cell lines, we extended the analysis to an in vivo apoptosis model. In the thymus, TCR triggering leads to immature thymocyte elimination (negative selection). This process can be mimicked in F5-TCR mice by the injection of the antigen specifically recognized by the TCR, which leads to massive apoptosis of immature thymocytes (CD4 + CD8 + ). Interestingly, PARP processing and DNA fragmentation could be detected in treated mouse thymocytes as early as 90 min after peptide injection, when no reduction in cell numbers had yet taken place, but not in thymocytes from control animals (PBS injected) (Fig. 9A, B) .
Thymocyte RNA was prepared either alone (−JHM12) or mixed with human control cells (+JHM12). Specific degradation of the two CD8α mRNA species was demonstrated, without significant degradation of control human mRNA (TCRβ) in the mixture (Fig. 9 C, D) . In this in vivo model, mRNA degradation also affected a fraction of the transcripts higher than the corresponding fraction of cells with fragmented DNA (cells in the sub-G 0 /G 1 phase of the cell cycle) (Fig. 9D) .
DISCUSSION
The data presented here demonstrate that mRNA degradation is a general early apoptosisinduced event and that it can be dissected from other processes that occur during programmed cell death. The hallmarks of apoptosis are 1) chromosomal DNA fragmentation into mono-and polynucleosomes, detectable as a DNA ladder (8); 2) caspase activation (47, 48) , which leads to cleavage of specific protein substrates (10, 11, 16, 48, 49) , and 3) phosphatidylserine exposure at the cell surface, detectable as annexin V binding (50) . Recent data showed that apoptosis induces a broad spectrum of changes in cellular proteins (12) . In addition, apoptosis-induced degradation of 28S rRNA (18, 51, 52), mitochondrial 16S rRNA (53) , and the Ro ribonucleoproteinassociated Y RNAs (19) has been reported, although so far nothing was known about the fate of cytoplasmic mRNAs.
The data reported here demonstrate degradation of cytoplasmic mRNAs during apoptosis. Specificity was shown by mixing experiments in which mRNAs derived from apoptotic cells were degraded, whereas control cell mRNAs remained intact. Apoptosis-induced mRNA degradation is not restricted to genes with a specific function, because besides 28S rRNA, the mRNAs analyzed encode proteins implicated in cell type-specific functions, proteins such as HLA-I, IAα, TCRβ, and CD69; structural proteins such as β-actin; and proteins involved in the control of cell survival, such as BAX.
Apoptosis-induced specific RNA degradation is neither cell line nor species restricted, because it was observed in nontransformed mouse T-cell lines (CTLL-2) (Fig. 5) , mouse B-cell lymphomas (A20) (Figs. 4, 6, and 7) , human T-cell leukemias (Jurkat) (Figs. 1, 2, 6 , and 8), and T-cell lymphomas (Molt-4) (not shown), as well as in mouse thymocytes in vivo (Fig. 9) .
Furthermore, mRNA degradation, rather than being restricted to an apoptosis signaling pathway, was observed after triggering through Fas-mediated signaling pathways (CD95 cross-linking or AICD) (Figs. 1, 2 , and 4) (41, 54, 55), as well as by stimuli such as growth factor deprivation (Fig. 5) and okadaic acid treatment (data not shown), both independent of Fas (29, (56) (57) (58) .
Taken together, these data indicate that apoptosis-induced mRNA degradation is not restricted by stimulus, cell line, or species and that it affects all mRNAs analyzed, which suggests that mRNA degradation is, at least in lymphocytes, a general feature of the cell death program. Indeed, in this report we demonstrate that mRNA degradation occurs upon apoptosis triggering by stimuli not requiring de novo transcription or translation, such as direct Fas triggering (Figs.  1, 4, 6, 7, and 8) , and also upon AICD and growth factor deprivation (Figs. 2 and 5) , both of which do require transcription and translation.
Kinetics studies showed that after Fas triggering or AICD, mRNA degradation precedes DNA degradation and correlates with the appearance of the early apoptotic marker annexin V (Figs. 1,  2 , and 4). When apoptosis is induced by growth factor deprivation, however, the appearance of annexin V-positive cells and DNA fragmentation, which are preceded by mRNA degradation, have similar kinetics (Fig. 5) . This result indicates that apoptosis-induced specific mRNA degradation is an early event and not simply the consequence of the metabolic collapse of the cell.
mRNA degradation is an active process rather than the consequence of an apoptosis-induced transcriptional blockade. Indeed, the intrinsic half-life of CD69 mRNA was very short (about 20 min, Fig. 3) , and apoptosis induced an apparent stabilization, as demonstrated by the slower decay of the mRNA (about 1.5 h, Fig. 2) . Conversely, for other mRNAs (HLA-I, β-actin, and TCRβ) with intrinsic long half-lives (>10 h, Fig. 3 ), apoptosis-induced degradation led to an increased turnover (about 2-3 h, Fig. 2 ). Apoptosis-induced degradation kinetics for all mRNAs analyzed were very similar (β-actin, TCRβ, HLA-I, IAα, CD69, and BAX) (Figs. 1, 2 , and 4) and obviously independent of the intrinsic half-lives of the mRNAs in the cell.
Unlike β-actin, TCRβ, or HLA-I transcripts, CD69 mRNA contains AU-rich elements (ARE) in its 3'-untranslated region (42) , which destabilize otherwise stable mRNAs (59) . Tight control of ARE-containing transcript stability occurs through interaction of these cis-regulatory elements with specific binding proteins involved in mRNA turnover (60) . Apoptosis-induced CD69 mRNA decay has different, slower kinetics than its estimated half-life, which indicates that a mechanism different from ARE-mediated decay is implicated in apoptosis-induced degradation. Non-ARE-containing mRNAs are also degraded during apoptosis, although with faster kinetics than their corresponding half-lives, indicating that a specific mechanism is responsible for mRNA degradation triggered by apoptosis. This further substantiates the idea that mRNA degradation is a generalized feature of the apoptotic program.
In addition, the general caspase inhibitor Z-VAD-fmk (61) inhibited expression of all apoptotic markers including mRNA degradation (Fig. 6) , whereas the more restricted caspase inhibitor p35, which completely blocks CD95-induced apoptosis, was unable to fully abrogate mRNA degradation (Fig. 8) . The molecular mechanisms implicated in apoptosis-induced mRNA degradation are unknown. Nonetheless, it could be speculated that mRNA degradation depends on an upstream apical caspase (inhibited by Z-VAD-fmk but not p35) unable to cleave PARP. Conversely, it might be envisaged that in addition to caspases, Z-VAD-fmk inhibits other molecules (not inhibited by p35), including those responsible for RNase activation.
Kinetic analysis with caspase inhibitors not only allowed delineation of conditions in which mRNA degradation occurs in the absence of annexin V binding or DNA or PARP degradation but also demonstrated that the mechanisms involved in mRNA degradation were fully active as early as 0.5 h after Fas cross-linking, whereas inhibition of other apoptotic hallmarks was progressively abrogated (Fig. 7) . These findings strongly suggest that the signaling pathways induced by anti-Fas mAb can be kinetically dissociated into one route leading to mRNA degradation and another one leading to PARP processing, annexin V binding, and DNA fragmentation. The baculoviral p35 experiments (Fig. 8) corroborated the notion that a distinct signaling pathway is responsible for mRNA degradation during apoptosis. Furthermore, extensive mRNA degradation, although apparently a general early apoptotic event, is not sufficient to induce cell death per se.
During maturation, thymocytes are subject to positive and negative selection processes, in which the large majority of cells die by apoptosis; only about 5% of cells successfully complete maturation. The negative selection process has been mimicked in vivo in TCR transgenic mice by antigen injection, which leads to the elimination of the vast majority of CD4 + CD8 + thymocytes (36, 40) . Specific mRNA degradation in these cells was demonstrated as early as 90 min after antigen injection, preceding DNA degradation. This finding was thus a clear indication that apoptosis-induced mRNA degradation is a general early event that occurs not only in T-cell lines but also in vivo.
These observations raise a question about the nature of the RNases involved, which remains to be elucidated. By analogy to the CAD, which after cleavage of its specific inhibitor ICAD is activated and translocates to the nucleus (16), a similar model can be envisaged for a caspaseactivated RNase. CAD itself cannot be responsible for degradation of mRNA because 1) under conditions in which CAD was inhibited, there was still 28S rRNA degradation (18, 33) , 2) kinetic analysis with caspase inhibitors allowed differentiation of conditions in which mRNA degradation occurs in the absence of DNA degradation (Fig. 7), 3 ) similar results were obtained in Jurkat cells constitutively expressing the caspase inhibitor p35 (Fig. 8) , and 4) the presence in Jurkat cells of DEVD (a caspase-3 inhibitor) prevented DNA fragmentation induced by anti-CD95 mAb, whereas the mRNA was still degraded (not shown).
Detailed molecular analysis of apoptosis-induced 28S rRNA degradation products suggests that RNase L may be the RNase involved (51, 62) . RNase L is found in nearly all mammalian cell types and tissues (63) and was initially described as an interferon-inducible enzyme (63) . RNase L −/− mice show defective apoptosis in the thymus and spleen; in vitro thymocyte-and fibroblastinduced apoptosis is also defective (62) . These findings, together with the similar decay kinetics of 28S rRNA and mRNAs, allow us to hypothesize that RNase L may be one of the enzymes implicated in apoptosis-induced mRNA degradation. RNase L cleavage of 28S rRNA gives a defined pattern of readily detectable degradation intermediates (51, 62) , similar to the pattern observed in the experiments presented here (Figs. 1, 2 , and 4-7). For cytoplasmic mRNAs, however, degradation intermediates remained elusive so far (Figs. 1, 2 , and 4-7), which may be due to the high degradation rate and the intrinsic difficulty of detecting degradation intermediates from transcripts of low or intermediate abundance or conversely may be interpreted as the involvement of different RNases in the degradation of cytoplasmic mRNAs. Further experiments are needed to identify RNase activities responsible for degradation of the bulk of cytoplasmic mRNAs.
Thus, apoptosis induces degradation of the cytoplasmic mRNAs but also degradation of 28S rRNA and cleavage of translation initiation factors (eIF4GI, eIF4GII) (64, 65), which suggests that the cell, by different means, blocks protein synthesis, which may be a prerequisite for reaching the "point of no return" in the cell death program. Furthermore, degradation of cellular mRNA is a general early apoptotic event, which may be considered a hallmark of apoptosis. This finding has clear implications in the field of mRNA turnover, as well as for the physiology of apoptosis, because it demonstrates for the first time a generalized change in mRNA stablility induced by an external stimuli and, in addition, will have to be taken into account in experiments aimed at identifying genes involved in the cell death process. 
